Flow cytometry

KCAS Bio and Crux Biolabs Announce Global Spectral Flow Cytometry Alliance

Retrieved on: 
Friday, May 3, 2024
Research, Clinical Trials, Health Technology, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, Contract research organization, Vitruvian Partners, Partnership, Investment, Partner, Flow cytometry

KCAS Bio has partnered with Crux Biolabs, a leading provider of flow cytometry and bioanalytical services located in Melbourne, Australia.

Key Points: 
  • KCAS Bio has partnered with Crux Biolabs, a leading provider of flow cytometry and bioanalytical services located in Melbourne, Australia.
  • John Bucksath, CEO of KCAS Bio, commented, “We are delighted to partner with the Crux Biolabs team, working to accelerate our combined offering of global development support to the industries and customers we serve.
  • KCAS Bio has embarked on significant investments in spectral flow cytometry, including the placement of harmonized Cytek Aurora cytometers at Crux Biolabs.
  • Establishing common practices and using a harmonized Cytek Aurora platform for spectral flow cytometry with KCAS Bio will bring a unique and industry-leading offering to our current and emerging clients.”

Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry

Retrieved on: 
Friday, May 3, 2024
Laboratory, Head, Laminar, Partnership, Doctor of Philosophy, Research, Vaccine, Automation, Flow cytometry

The agreement combines the Laminar flow-based gentle liquid exchange technology known as C-FREE™ technology from Curiox with the comprehensive suite of DURAClone dry pre-formulated antibody panels and customized DURA Innovations dry reagent antibody cocktails from Beckman Coulter Life Sciences.

Key Points: 
  • The agreement combines the Laminar flow-based gentle liquid exchange technology known as C-FREE™ technology from Curiox with the comprehensive suite of DURAClone dry pre-formulated antibody panels and customized DURA Innovations dry reagent antibody cocktails from Beckman Coulter Life Sciences.
  • This workflow solution overcomes longstanding challenges faced by researchers worldwide, including the need for highly standardized, reproducible, and automated sample preparation for flow cytometry laboratories.
  • "Our alliance with Beckman Coulter Life Sciences is not just about combining technologies; it's about combining our strengths to empower the scientific community," said Namyong Kim.
  • "This partnership presents an exciting step forward in redefining the standards of quality and efficiency in flow cytometry research.

Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution

Retrieved on: 
Wednesday, May 1, 2024
Hardware, Science, Research, Technology, Software, Agilent Technologies, Conference, Flow cytometry, Laser, Acquisition, Drug discovery, Wang

Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility.
  • The NovoCyte Opteon represents a significant leap forward in flow cytometry technology, with configurations ranging from three to five lasers and support for up to 73 high-quality detectors.
  • It meets researchers’ needs for sophisticated, large-panel flow cytometry assays while maintaining the easy-to-use features of the NovoCyte portfolio.
  • Agilent will officially unveil the NovoCyte Opteon at the CYTO 2024 Conference in Edinburgh, Scotland, happening May 4 – 8, 2024.

BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes

Retrieved on: 
Tuesday, April 30, 2024
Science, Biotechnology, Research, Oncology, Health, Artificial Intelligence, Technology, Genetics, Patient, Machine learning, Immunotherapy, MD, Doctor of Philosophy, IO, Toxicity, Multimedia, Biomarker, Flow cytometry

This press release features multimedia.

Key Points: 
  • This press release features multimedia.
  • BostonGene’s revolutionary immunoprofiling incorporates flow cytometry and RNA-sequencing to track changes in the peripheral blood, which will be correlated with genetic variations from germline DNA testing to uncover blood-based signatures with immunotherapy response, resistance and toxicity.
  • “PICI’s mission-focused collaboration with BostonGene is a significant step toward unlocking the potential of blood-based biomarkers to advance personalized immunotherapy,” said Tarak Mody, PhD, Chief Business Officer at PICI.
  • Together, we're pioneering the search for blood-based biomarkers," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Global Research Antibodies & Reagents Market Outlook & Forecasts, 2023 and 2024-2029: Growing Demand for Precision Medicine, Rising Focus on Biomarker Discovery, & Rise in Proteomics and Genomics - ResearchAndMarkets.com

Retrieved on: 
Friday, April 12, 2024
Health, Stem Cells, Genetics, Research, Science, Biotechnology, USD, Immunoprecipitation, Antibody, Cancer, Genomics, Protein, Cell biology, ELISA, Heart, Personalized medicine, Proteomics, Immunohistochemistry, Biomedical Research, Biomarker, Growth, University, Disease, ChromeOS, Bio-Rad Laboratories, Therapy, Northern blot, Patient, Chemistry, Medicine, Diagnosis, Antigen, Gene expression, Genome, Elisa's, Drug development, Biology, Molecular biology, Drug discovery, Thermo Fisher Scientific, Gene, Flow cytometry, Fine chemical

North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.

Key Points: 
  • North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.
  • This paradigm shift presents a substantial opportunity for the research antibodies & reagents market, an essential component of precision medicine research.
  • The reagents product type accounted for the most significant global research antibodies & reagents market share in 2023.
  • The academics & research institutes and research labs end-user segment dominated the global research antibodies & reagents market share in 2023.

Nodexus Adds Flow Cytometry Leaders to Scientific Advisory Board

Retrieved on: 
Wednesday, April 10, 2024
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Breast cancer, Science Publishing Group, Immortalised cell line, University, International Society, ISAC, Jonni, SAB, CRISPR, Cell biology, Hospital, Seminal vesicles, Medical laboratory, Doctor of Philosophy, Pathology, Protein engineering, Therapy, New York Blood Center, Chairperson, Synthetic biology, Cardiovascular disease, Malignancy, Assistant, Inc., NX, HIV, Biomarker, Associate, SICS, AAPS, Flow cytometry

Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).

Key Points: 
  • Nodexus Inc., a leader in automated benchtop single-cell characterization and microfluidic isolation technologies, today announced that three leading experts in cytometry sciences, pathology, and cancer biology have joined its Scientific Advisory Board (SAB).
  • The Nodexus SAB is chaired by Professor Jonni Moore, PhD, one of the world’s leading experts in flow cytometry, laboratory medicine, and cellular immunology.
  • He is a founding member of the Southern California Flow Cytometry Association (SoCal Flow) and the American Association of Pharmaceutical Scientists (AAPS) PharmaFlow Working Group.
  • “I’m extremely pleased to serve as the Chairperson of Nodexus’ Scientific Advisory Board,” said Dr. Moore.

Abzena Launches EpiScreen® 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics and Bioconjugates

Retrieved on: 
Thursday, April 25, 2024
Protein engineering, CDMO, Therapy, Risk, Proteomics, Patient, Spacecraft, CSO, Flow cytometry, Vaccine

The next generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early phase development.

Key Points: 
  • The next generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early phase development.
  • Abzena launched its first generation EpiScreen® platform over 20 years ago and are considered to be innovators in the field of immunogenicity .
  • Dr Campbell Bunce, CSO of Abzena said, "Understanding a lead drug candidate's immunogenicity risk profile and how we can mitigate it is a key step in advancing new drugs from discovery to clinical trials.
  • Our EpiScreen® 2.0 platform allows drug developers to be better informed and more confident in progressing to later stage development with a better chance of success in patients."

Abzena Launches EpiScreen® 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics and Bioconjugates

Retrieved on: 
Thursday, April 25, 2024
Protein engineering, CDMO, Therapy, Risk, Proteomics, Patient, Spacecraft, CSO, Flow cytometry, Vaccine

The next generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early phase development.

Key Points: 
  • The next generation tool provides a better immunogenic assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early phase development.
  • Abzena launched its first generation EpiScreen® platform over 20 years ago and are considered to be innovators in the field of immunogenicity .
  • Dr Campbell Bunce, CSO of Abzena said, "Understanding a lead drug candidate's immunogenicity risk profile and how we can mitigate it is a key step in advancing new drugs from discovery to clinical trials.
  • Our EpiScreen® 2.0 platform allows drug developers to be better informed and more confident in progressing to later stage development with a better chance of success in patients."

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Retrieved on: 
Thursday, April 25, 2024
Infection, Congress, Recombinant antibodies, SARS-CoV-2, Long, Viral, ELISA, ESCMID, Cytokine, Epitope, Lyme disease, Research, ELISpot, Immunology, Diagnosis, Long COVID, Biomarker, Immunity, Flow cytometry, CD8, Vaccine

The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.

Key Points: 
  • The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners.
  • "We are very pleased to launch ImmuneSelect, an important portfolio of immune profiling solutions within our ViraxImmune™ T-Cell diagnostic platform," commented Mr. James Foster, Chief Executive Officer of Virax Biolabs.
  • "The launch marks a significant milestone for Virax as it brings us a step closer to commercializing ViraxImmune™ as a full In-Vitro-Diagnostic product."
  • ImmuneSelect is the Company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity.

Dotmatics Luma Lab Connect Unlocks the Untapped Value of Lab Instrument Data to Accelerate Scientific R&D Decision-Making

Retrieved on: 
Thursday, April 11, 2024
Immortalised cell line, Metadata, EDT, Laboratory, AI, Outline, Conference, Research, Software as a service, JDBC, Dotmatics, Data management, FAIR, Associate, API, Organization, Medication, Flow cytometry, Medical device

BOSTON, April 11, 2024 /PRNewswire/ -- Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, today announced the launch of Luma™ Lab Connect, helping R&D laboratories automatically ingest data from instruments or data sources and centralize it in one place to increase accuracy and accelerate decision-making. Luma Lab Connect extracts descriptive metadata and experiment results from files and makes data available from across labs and experiments enabling deeper exploration, analysis, and insights on one harmonized, low-code cloud platform, Dotmatics Luma™. Learn more about Luma Lab Connect.

Key Points: 
  • "With Luma Lab Connect, Dotmatics is helping labs unlock the value of their data," - Thomas Swalla, CEO at Dotmatics.
  • "With Luma Lab Connect, Dotmatics is helping labs unlock the value of their data by providing a unified, low-code solution for instrument connectivity, data harmonization, and modeling," said Thomas Swalla, CEO at Dotmatics.
  • Our customers who have already adopted Luma Lab Connect are finding immense value from their instrument data, simplifying workflows, and accelerating scientific discovery."
  • By automating the real-time flow of lab instrument data into the Luma data management platform, Luma Lab Connect eliminates manual processes, streamlining connectivity and enhancing data accuracy without requiring coding expertise.